drugset / Trial / NCT00352677
Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and effectiveness of INNO-406 in adult patients with imatinib-resistant or intolerant Philadelphia chromosome-positive (Ph+) leukemias.
Timeline
- Start
- 2006-07
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bafetinib | Small molecule | 10 mg | Oral |
| Subject | Bafetinib | Small molecule | 50 mg | Oral |